Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
213Bi-matuzumab
- Development stage
- Unknown
- Lead developer
- Technical University of Munich
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravesical
01
Overview
213Bi-matuzumab is an experimental radiopharmaceutical and antibody-drug conjugate (ADC) consisting of the humanized monoclonal antibody matuzumab conjugated to the alpha-emitting radionuclide Bismuth-213 (^213Bi). Developed through a collaboration between the Technical University of Munich and the European Commission's Joint Research Centre, it specifically targets the epidermal growth factor receptor (EGFR), which is frequently overexpressed in various malignancies. Upon binding to EGFR on tumor cells, the conjugate delivers high-energy, short-range alpha radiation that induces lethal DNA double-strand breaks. This mechanism is particularly effective in treating hypoxic tumor cells and minimizing damage to surrounding healthy tissue. It has been primarily investigated for the intravesical treatment of BCG-refractory carcinoma in situ of the bladder, as well as for glioblastoma and squamous cell carcinoma.
- Other names
- 213Bi-anti-EGFR-mAb213Bi-DOTA-matuzumab
02
Targets
Beyond the preview
Go deeper on 213Bi-matuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 213Bi-matuzumab.